Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | Silo Pharma, Inc.: Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform | 164 | GlobeNewswire (Europe) | Targeting Multi-Chain Digital Asset Growth and Decentralized Finance (DeFi) Integration SARASOTA, FL, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO), today announced the launch... ► Artikel lesen | |
29.07. | Silo Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
16.07. | Silo Pharma completes dosing in FDA-requested safety study for PTSD drug | 2 | Investing.com | ||
SILO PHARMA Aktie jetzt für 0€ handeln | |||||
16.07. | Silo Pharma, Inc.: Silo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15 | 158 | GlobeNewswire (Europe) | SARASOTA, FL, July 16, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery... ► Artikel lesen | |
10.07. | Silo Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
07.07. | Silo Pharma expects SPC-15 PTSD drug preclinical data within 90 days | 1 | Investing.com | ||
07.07. | Silo Pharma, Inc.: Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025 | 437 | GlobeNewswire (Europe) | Planned submission of IND application in 2025; Phase 1 clinical trial to follow if IND application approved No new PTSD drug approvals in the U.S. in nearly 25 years; large potential addressable market... ► Artikel lesen | |
03.07. | Silo Pharma erhält Nasdaq-Mitteilung über Nichteinhaltung des Mindestangebotspreises | 1 | Investing.com Deutsch | ||
03.07. | Silo Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
25.06. | Silo Pharma, Hoth Therapeutics Enter LOI to Develop Obesity Treatment | 1 | Contract Pharma | ||
25.06. | Hoth Therapeutics, Inc: Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market | 330 | JCN Newswire | NEW YORK, June 25, 2025 - (ACN Newswire) - Silo Pharma, Inc. (Nasdaq: SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery... ► Artikel lesen | |
25.06. | Silo Pharma to form JV with Hoth Therapeutics for obesity treatment | 1 | Seeking Alpha | ||
25.06. | Silo Pharma and Hoth Therapeutics plan joint venture for obesity treatment | 2 | Investing.com | ||
25.06. | Hoth Therapeutics, Silo Pharma Launch JV To Commercialize VA-Invented Obesity Drug | - | RTTNews | ||
25.06. | Silo Pharma, Inc.: Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market | 160 | GlobeNewswire (Europe) | Technology Co-Developed by the U.S. Department of Veterans Affairs and Emory University NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) ("Silo" or the "Company"), a developmental... ► Artikel lesen | |
11.06. | Silo Pharma, Inc.: Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears | 454 | GlobeNewswire (Europe) | SARASOTA, FL, June 11, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery... ► Artikel lesen | |
05.06. | Silo Pharma stock surges on Bitcoin reserve move | 1 | Investing.com | ||
05.06. | Silo Pharma allocates $1 million to Bitcoin holdings | 1 | Investing.com | ||
05.06. | Silo Pharma, Inc.: Silo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset | 284 | GlobeNewswire (Europe) | SARASOTA, FL, June 05, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery... ► Artikel lesen | |
21.05. | Silo Pharma teams up with Resyca for IND-supporting intranasal drug-device study of PTSD drug | 1 | Seeking Alpha |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 96,15 | +0,16 % | Ihre wichtigsten Termine: Tyson Foods, Biontech, Adtran, Loews, VDMA und Stabilus stehen heute im Fokus! | © Foto: UnsplashGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 07:00 Uhr, Luxemburg:... ► Artikel lesen | |
CUREVAC | 4,660 | -0,09 % | EQS-News: CureVac kündigt Einigung zur Beilegung des Patentstreits mit Pfizer/BioNTech an | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Patent
CureVac kündigt Einigung zur Beilegung des Patentstreits mit Pfizer/BioNTech an
08.08.2025 / 02:15 CET/CEST
Für... ► Artikel lesen | |
AMGEN | 247,20 | -0,14 % | Amgen hebt Prognose nach überraschend gut verlaufenem Quartal an | THOUSAND OAKS (dpa-AFX) - Der US-Biotechkonzern Amgen blickt nach einem überraschend gut gelaufenen Quartal optimistischer auf 2025. Der Umsatz dürfte bei 35 bis 36 Milliarden US-Dollar liegen, teilte... ► Artikel lesen | |
NOVAVAX | 7,220 | +0,36 % | Novavax, Inc.: Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights | Total revenue of $239 million in the second quarter of 2025
Received FDA BLA approval for Nuvaxovid, the only recombinant protein-based, non-mRNA COVID-19 vaccine... ► Artikel lesen | |
BIOGEN | 111,70 | -0,49 % | Biogen-Aktie: Kurs mit wenig Bewegung (114,5994 €) | Im US-amerikanischen Wertpapierhandel ist das Wertpapier von Biogen derzeit unauffällig. Die Aktie kostete zuletzt 132,69 US-Dollar. Ein geringes Kursplus von 0,38 Prozent zeigt die Kurstafel für die... ► Artikel lesen | |
ILLUMINA | 81,02 | -0,28 % | Illumina Settles With DOJ, Veterans To End Whistleblower Lawsuit | ||
CRISPR THERAPEUTICS | 46,800 | -1,27 % | Abivax, CRISPR Therapeutics und Revolution Medicines: Biotech im Höhenflug - das wikifolio ... | ||
MAINZ BIOMED | 1,440 | -0,69 % | Mainz BioMed NV: Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants | BERKELEY, Calif. and MAINZ, Germany, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), a molecular genetics diagnostic company specializing in the... ► Artikel lesen | |
VIKING THERAPEUTICS | 32,740 | +0,63 % | Doppelschlag mit Viking Therapeutics und Rheinmetall | An der Börse gibt es Momente, in denen wenige Tage über den Erfolg einer ganzen Strategie entscheiden. Wer solche Chancen erkennt und entschlossen handelt, kann in kurzer Zeit außergewöhnliche Ergebnisse... ► Artikel lesen | |
INTELLIA THERAPEUTICS | 9,236 | -0,39 % | Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus | ||
EDITAS MEDICINE | 1,910 | +0,84 % | Editas Medicine, Inc.: Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology ... | Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement... ► Artikel lesen | |
GENMAB | 187,00 | +0,43 % | Genmab Reports Strong H1 2025 Results Driven By Higher Royalties And Product Sales | COPENHAGEN (dpa-AFX) - Genmab A/S (GMAB) posted performance results on Thursday for the first half of 2025, with revenue rising 19 percent year-over-year to $1.64 billion, up from $1.38 billion... ► Artikel lesen | |
TEMPUS AI | 52,00 | -0,95 % | Tempus AI: 90 Prozent Wachstum - KI-Aktie hebt ab | Das US-Unternehmen Tempus AI hat am Freitagmittag die Zahlen für das abgelaufene zweite Quartal vorgelegt. Sowohl bei Umsatz als auch Ergebnis je Aktie konnte der KI-Spezialist besser ab als vom Markt... ► Artikel lesen | |
BIOCRYST PHARMACEUTICALS | 7,228 | +1,32 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted... ► Artikel lesen | |
SAREPTA THERAPEUTICS | 15,785 | +0,80 % | What 43 Analyst Ratings Have To Say About Sarepta Therapeutics |